On behalf of the investigators of the Phase 3 CROWN Trial, we presented data, I presented the data about the comprehensive genomic analysis both in the ctDNA and tumor tissue. And the CROWN Phase 3 Trial was a trial exploring the role of lorlatinib in comparison with crizotinib in previously treated ALK fusion positive advanced non-small cell lung cancer, and the lorlatinib improved the PFS versus crizotinib, and we identify molecular correlates of response...
On behalf of the investigators of the Phase 3 CROWN Trial, we presented data, I presented the data about the comprehensive genomic analysis both in the ctDNA and tumor tissue. And the CROWN Phase 3 Trial was a trial exploring the role of lorlatinib in comparison with crizotinib in previously treated ALK fusion positive advanced non-small cell lung cancer, and the lorlatinib improved the PFS versus crizotinib, and we identify molecular correlates of response. And in particular, the PFS of lorlatinib was much of significantly superior than the PFS in the crizotinib arm, irrespectively of the EML4-ALK variants, and both in the ctDNA and in the tumor tissue and was significantly superior even in patients with bypass preexisting aberrations like MAP kinase, or RTK, or a PI 3-Kinase mTOR. And was significantly superior even in patients with TP53 positive mutation, although the presence of a patient in the TP53 might reduce slightly the efficacy of lorlatinib.
So the strength of lorlatinib as first line treatment for this patients has been demonstrated by the strength of the PFS, but also by the evidence that the efficacy is irrespective of the ALK variants, TP53, maybe. And also bypass preexisting mutations.